Abstract
Systemic amyloidosis, including light-chain (AL) and hereditary transthyretin (hATTR) types, is frequently underdiagnosed in its early stages. This study investigated the utility of [18F]florbetapir (FBP) and [18F]fluorodeoxyglucose (FDG) PET/CT for early detection and organ involvement evaluation. In a retrospective analysis of 83 participants (including AL, hATTR-PN, and plasma cell dyscrasias [PCD]), FBP PET demonstrated a sensitivity of 1.0 and specificity of 0.97, significantly outperforming FDG PET (sensitivity 0.63). Notably, FBP PET identified amyloid deposits in PCD patients before clinical symptoms of AL emerged. Both visual and quantitative (SUV/TBR) analyses of FBP PET provided comparable measures of organ involvement, suggesting that FBP PET is a highly sensitive, non-invasive tool for the early detection of systemic amyloidosis.
Introduction
Systemic amyloidosis is a group of life-threatening disorders characterized by the extracellular deposition of misfolded protein fibrils, leading to progressive organ dysfunction. The most common forms are light-chain (AL) amyloidosis, often associated with plasma cell dyscrasias (PCD), and hereditary transthyretin (hATTR) amyloidosis.
The clinical challenge lies in the "silent" progression of the disease. By the time symptoms such as heart failure or renal dysfunction manifest, organ damage is often advanced and irreversible. While tissue biopsy remains the diagnostic gold standard, its invasive nature and potential for sampling error limit its utility for early screening. Non-invasive imaging techniques are therefore critical. While [18F]FDG PET is a staple in oncology and inflammation imaging, its specificity for amyloid fibrils is limited. This study evaluates [18F]florbetapir (FBP)—a tracer originally developed for Alzheimer’s disease—as a potential superior alternative for detecting systemic amyloid deposits.
Methods
This retrospective study included 83 participants recruited between 2022 and 2024: 38 patients with AL amyloidosis, 8 with hATTR polyneuropathy (hATTR-PN), 28 with PCD, and 9 healthy controls. The hATTR-PN group was particularly notable for including patients with rare genetic mutations (p.H69R, p.A117S, p.K55N, and p.T69A) previously undocumented in amyloid PET literature.
All participants underwent whole-body PET/CT using [18F]FBP. A subset of 37 patients (AL and PCD) also received [18F]FDG PET scans for a head-to-head comparison. Researchers evaluated 20 different organs using both visual assessment and quantitative metrics, including Standardized Uptake Value (SUV) and Target-to-Background Ratio (TBR). Imaging findings were validated against clinical assessments, biochemical markers (e.g., NT-proBNP), and histological data.
Key Insights and Results
Superior Sensitivity and the Pre-Clinical Window
The most significant finding was the high diagnostic accuracy of [18F]FBP PET. It achieved a sensitivity of 1.0 and a specificity of 0.97 for detecting organ involvement. In direct comparison, FBP was markedly more sensitive than FDG (1.0 vs. 0.63). Crucially, FBP PET detected amyloid deposits in PCD patients who did not yet meet the clinical criteria for AL amyloidosis, suggesting a vital "pre-clinical" window for early intervention.
Molecular Mapping of Amyloid Types
The study revealed distinct distribution patterns for different amyloidosis types. Patients with hATTR-PN showed the highest tracer uptake in the muscles and kidneys, whereas AL patients exhibited significant involvement in the heart and kidneys. FBP PET also successfully visualized deposits in the vitreous body and nerves of patients with rare hATTR mutations, filling a significant gap in the current medical literature.
Practical Clinical Application
Quantitative analysis (SUV and TBR) showed that FBP uptake in the heart correlated strongly with NT-proBNP levels, a standard clinical marker for cardiac stress. Interestingly, the study found that visual analysis by expert readers was as effective as complex quantitative measurements. This finding is significant for clinical workflows, as it suggests that FBP PET scans can be reliably interpreted without the need for intensive computational post-processing.
Discussion and Limitations
While [18F]FBP PET represents a major advancement in non-invasive amyloid detection, some limitations remain. The tracer is naturally excreted through the hepatobiliary and urinary systems, which can create "background noise" that complicates the evaluation of the liver, gallbladder, and bladder. Additionally, while the study is large for a rare disease cohort, the control and hATTR groups were relatively small.
Because the study was retrospective, it did not track longitudinal outcomes to determine if early detection via FBP PET directly correlates with improved survival or specific rates of disease progression. Future research utilizing "total-body PET" scanners with a long-axial field-of-view could further enhance detection by capturing the brain and body simultaneously under identical physiological conditions.
Conclusion
[18F]florbetapir PET/CT is a highly sensitive and specific tool for the early detection of systemic amyloidosis, outperforming [18F]FDG PET and standard clinical assessments. Its ability to identify amyloid deposits in the pre-clinical phase of plasma cell dyscrasias offers a promising path toward earlier diagnosis and improved patient outcomes.
Summary updated